BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10586336)

  • 1. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
    Coiffier B; Neidhardt-Bérard EM; Tilly H; Belanger C; Bouabdallah R; Haioun C; Brice P; Péaud PY; Pico JL; Janvier M; Solal-Celigny P; Brousse N
    Ann Oncol; 1999 Oct; 10(10):1191-7. PubMed ID: 10586336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
    N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
    Cole BF; Solal-Céligny P; Gelber RD; Lepage E; Gisselbrecht C; Reyes F; Sebban C; Sugano D; Tendler C; Goldhirsch A
    J Clin Oncol; 1998 Jul; 16(7):2339-44. PubMed ID: 9667248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Sebban C; Mounier N; Brousse N; Belanger C; Brice P; Haioun C; Tilly H; Feugier P; Bouabdallah R; Doyen C; Salles G; Coiffier B
    Blood; 2006 Oct; 108(8):2540-4. PubMed ID: 16835383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
    Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
    J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
    Foussard C; Colombat P; Maisonneuve H; Berthou C; Gressin R; Rousselet MC; Rachieru P; Pignon B; Mahé B; Ghandour C; Desablens B; Casassus P; Lamy T; Delwail V; Deconinck E
    Ann Oncol; 2005 Mar; 16(3):466-72. PubMed ID: 15695500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
    Salles G; Mounier N; de Guibert S; Morschhauser F; Doyen C; Rossi JF; Haioun C; Brice P; Mahé B; Bouabdallah R; Audhuy B; Ferme C; Dartigeas C; Feugier P; Sebban C; Xerri L; Foussard C
    Blood; 2008 Dec; 112(13):4824-31. PubMed ID: 18799723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
    Bachy E; Houot R; Morschhauser F; Sonet A; Brice P; Belhadj K; Cartron G; Audhuy B; Fermé C; Feugier P; Sebban C; Delwail V; Maisonneuve H; Le Gouill S; Lefort S; Brousse N; Foussard C; Salles G;
    Haematologica; 2013 Jul; 98(7):1107-14. PubMed ID: 23645690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
    Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
    J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
    Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.
    Canioni D; Salles G; Mounier N; Brousse N; Keuppens M; Morchhauser F; Lamy T; Sonet A; Rousselet MC; Foussard C; Xerri L
    J Clin Oncol; 2008 Jan; 26(3):440-6. PubMed ID: 18086798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
    Wirt DP; Giles FJ; Oken MM; Solal-Celigny P; Beck JR
    Leuk Lymphoma; 2001 Feb; 40(5-6):565-79. PubMed ID: 11426529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte.
    Guerci A; Lederlin P; Reyes F; Bordessoule D; Sebban C; Tilly H; Kerneis Y; Biron P; Gisselbrecht C; Herbrecht R; Coiffier B
    Ann Oncol; 1996 Nov; 7(9):966-9. PubMed ID: 9006749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
    Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
    Brice P; Bastion Y; Lepage E; Brousse N; Haïoun C; Moreau P; Straetmans N; Tilly H; Tabah I; Solal-Céligny P
    J Clin Oncol; 1997 Mar; 15(3):1110-7. PubMed ID: 9060552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.